171 related articles for article (PubMed ID: 21772985)
1. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Bessho H; Kusuhara S; Tsukahara Y; Negi A
J Ophthalmol; 2011; 2011():742020. PubMed ID: 21772985
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
Matsumiya W; Honda S; Kusuhara S; Tsukahara Y; Negi A
BMC Ophthalmol; 2013 Apr; 13():10. PubMed ID: 23557322
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Ophthalmologica; 2015; 234(1):33-9. PubMed ID: 26112059
[TBL] [Abstract][Full Text] [Related]
4. Pigment epithelial tears after ranibizumab injection in polypoidal choroidal vasculopathy and typical age-related macular degeneration.
Shin JY; Choi M; Chung B; Byeon SH
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2151-60. PubMed ID: 25744335
[TBL] [Abstract][Full Text] [Related]
5. Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Hosokawa MM; Ouchi C; Shiode Y; Kimura S; Matoba R; Morita T; Morizane Y
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; ():. PubMed ID: 38625447
[TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan.
Honda S; Imai H; Yamashiro K; Kurimoto Y; Kanamori-Matsui N; Kagotani Y; Tamura Y; Yamamoto H; Ohoto S; Takagi H; Uenishi M; Negi A
Ophthalmologica; 2009; 223(5):333-8. PubMed ID: 19478533
[TBL] [Abstract][Full Text] [Related]
7. Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up.
Miki A; Honda S; Kojima H; Nishizaki M; Nagai T; Fujihara M; Uenishi M; Kita M; Kurimoto Y; Negi A;
Jpn J Ophthalmol; 2013 May; 57(3):301-7. PubMed ID: 23508554
[TBL] [Abstract][Full Text] [Related]
8. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
[TBL] [Abstract][Full Text] [Related]
9. One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Sakurai M; Baba T; Kitahashi M; Yokouchi H; Kubota-Taniai M; Bikbova G; Oshitari T; Yamamoto S
Clin Ophthalmol; 2014; 8():235-41. PubMed ID: 24511222
[TBL] [Abstract][Full Text] [Related]
10. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Bessho H; Honda S; Kondo N; Negi A
Mol Vis; 2011 Apr; 17():977-82. PubMed ID: 21541271
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan.
Honda S; Kurimoto Y; Kagotani Y; Yamamoto H; Takagi H; Uenishi M;
Jpn J Ophthalmol; 2009 Nov; 53(6):593-597. PubMed ID: 20020237
[TBL] [Abstract][Full Text] [Related]
13. Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration.
Tanaka A; Hata M; Tsuchikawa M; Ueda-Arakawa NU; Tamura H; Miyata M; Takahashi A; Kido A; Muraoka Y; Miyake M; Ooto S; Tsujikawa A
Clin Ophthalmol; 2024; 18():507-516. PubMed ID: 38405104
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity.
Mori R; Tanaka K; Yuzawa M
Medicine (Baltimore); 2018 Jun; 97(25):e11188. PubMed ID: 29924037
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study.
Sakamoto S; Takahashi H; Inoue Y; Arai Y; Inoda S; Kakinuma N; Fujino Y; Tanabe T; Kawashima H; Yanagi Y
Clin Ophthalmol; 2018; 12():1137-1147. PubMed ID: 29970955
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
[TBL] [Abstract][Full Text] [Related]
18. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
19. Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy.
Liu L; Ma J; Duan P; Liu Y; Yin ZQ
Mol Vis; 2015; 21():1130-41. PubMed ID: 26539025
[TBL] [Abstract][Full Text] [Related]
20. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
